Results were announced from a phase 3 trial evaluating solriamfetol for major depressive disorder with/without severe excessive daytime sleepiness.

Irish biopharmaceutical company Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic hypersomnia (IH). The double-blind, ...

Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic ...

The Canadian Red Cross is offering personalized recovery support to people impacted by the flooding and extreme weather event in British Columbia that took place on November 14, 2021. The Red Cross ...